Concepedia

Nayyar Iqbal

NI

72

Publications

8.2K

Citations

38

H-Index

1999

Active since

Affiliations

AstraZeneca (United States)(Current)

Bristol-Myers Squibb (United States)

University of Pennsylvania

AstraZeneca (Sweden)

Veterans Health Administration

Nayyar Iqbal is an author at AstraZeneca (United States) specializing in medicine, diabetes, and metabolic syndrome.

Top concepts

Publications per year

1999–2023

72

Publications

72

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

Rury R. Holman, M. Angelyn Bethel, Robert J. Mentz et al. · New England Journal of Medicine · 2017 · 2.1K citations · Full text

A Low-Carbohydrate as Compared with a Low-Fat Diet in Severe Obesity

Frederick F. Samaha, Nayyar Iqbal, Prakash Seshadri et al. · New England Journal of Medicine · 2003 · 1.3K citations · Full text

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

Clifford J. Bailey, J. L. Gross, Delphine Hennicken et al. · BMC Medicine · 2013 · 355 citations · Full text

The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects

Xinhua Chen, Nayyar Iqbal, Guenther Boden · Journal of Clinical Investigation · 1999 · 292 citations · Full text

Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin

Julio Rosenstock, Lars Hansen, Pamela Zee et al. · Diabetes Care · 2014 · 280 citations

Rows per page

1–5 of 72